Side effects of therapy of hepatitis C and their management.
about
MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteinsSafety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety TrialNeed of cost-effective vaccines in developing countries: What plant biotechnology can offer?MicroRNAs Expressed during Viral Infection: Biomarker Potential and Therapeutic ConsiderationsHepatitis C virus infection and thyroid autoimmune disorders: A model of interactions between the host and the environmentHepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antiviralsPsychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implicationsNatural history and clinical response: "it's the virus, stupid, or is it the host?"Chutes and ladders in hepatitis C nucleoside drug developmentA pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infectionHigh-Affinity Aptamers to Subtype 3a Hepatitis C Virus Polymerase Display Genotypic SpecificityInterferon alpha therapy for hepatitis C: treatment completion and response rates among patients with substance use disordersComprehensive Analysis of the Effects of Ordinary Nutrients on Hepatitis C Virus RNA Replication in Cell CultureInvestigating Toll-Like Receptor Agonists for Potential To Treat Hepatitis C Virus InfectionG-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrenceMK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A ProteaseHepatitis C: a clinical reviewInterleukin-6 haplotypes and the response to therapy of chronic hepatitis C virus infectionPharmacokinetic-Pharmacodynamic Modeling of Alpha Interferon Response Induced by a Toll-Like 7 Receptor Agonist in MiceThe Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease InhibitorsInterferon therapy in hepatitis C leading to chronic type 1 diabetesPrices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic AnalysisITPA Polymorphisms Are Associated with Hematological Side Effects during Antiviral Therapy for Chronic HCV InfectionPatient and provider characteristics associated with the decision of HIV coinfected patients to start hepatitis C treatment.T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitroInfluence of a priori Information, Designs, and Undetectable Data on Individual Parameters Estimation and Prediction of Hepatitis C Treatment Outcome.The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation.Life-threatening thrombocytopenia and nephrotic syndrome due to focal segmental glomerulosclerosis associated with pegylated interferon alpha-2b and ribavirin treatment for hepatitis C.L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-α 2b plus ribavirin.Platelet count and sustained virological response in hepatitis C treatment.Type B insulin resistance developing during interferon-alpha therapy.Late-Onset Immune Thrombocytopenic Purpura After Withdrawal of Interferon Treatment for Chronic Hepatitis C Infection: A Case ReportNutrigenomics therapy of hepatisis C virus induced-hepatosteatosis.In vitro and in vivo antioxidative and hepatoprotective activity of aqueous extract of Cortex Dictamni.Cryptococcal meningitis in a patient with chronic hepatitis C treated with pegylated-interferon and ribavirinLiving with Hepatitis C Virus: A Systematic Review and Narrative Synthesis of Qualitative Literature.Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literatureFactors that influence an HIV coinfected patient's decision to start hepatitis C treatmentElimination of hepatitis C virus from hepatocytes by a selective activation of therapeutic molecules.Assessment of health-related quality of life in antiviral-treated Taiwanese chronic hepatitis C patients using SF-36 and CLDQ
P2860
Q24630291-5F0DE99B-05CD-466A-A94D-322C5895A519Q24683611-D39D971B-4C6E-47DD-8661-D0546CD9F876Q26769942-9E62EE0D-8668-47CB-9318-8155FDC7D264Q26773183-00CA963F-EB21-4766-BA03-384C7B85C582Q26775018-E0EA1896-984A-4B0C-A479-7B0E9ABA1764Q26782033-4E4CEE82-513B-4324-96B0-FAE599D4BD34Q26798477-FBBEC139-7281-4C24-84D6-7FE60DDC1DA2Q26824094-786F6118-3797-4EBF-9189-7F55DD82F55BQ26998630-F0B18AAD-9486-4628-B10B-3BF313FCE141Q27023355-266B6C41-4F60-4374-A843-955851EF08B1Q27477457-ECFC3569-478F-4186-9F5E-371D55A6D7A2Q27477998-C4C41497-F01D-480C-B951-9DC525B57B05Q27480270-F1FB2260-A041-4A2C-A2A6-B1353E6BA66AQ27480922-B29DA06E-8FE7-4CD0-8A7C-33917F16E246Q27490405-A3825D0C-8E71-4B33-B1E5-C3E368124D3FQ27490545-7451715F-050E-4B26-8523-882DA7576B19Q27490788-B1A59CBA-E64F-4EC7-9A95-333339A22153Q27490833-C8BBB744-69B5-4C3C-9857-8A59A86BA6FCQ27490955-9F66AD5B-1455-46B4-8ED0-ED3893347E0AQ27671640-40400FB6-2F98-4697-89C0-F04A40DE54C4Q28080876-CC9BB955-A6A5-4C9E-9C69-07D62D7D47A8Q28552507-9F6A7C32-0049-4537-908A-F00E32CF624CQ28606732-30104B20-D637-4F4A-AFC8-A9AE33C94F17Q30405780-BEBCE09C-8FDA-4707-A9D0-7AA88CCDBBE7Q30426020-07388E37-4798-4512-B865-9C52CEEE59EAQ30655795-A9C8842F-5E95-4BA1-B8F2-E6A15903E959Q33365990-2881B85A-FC12-4F77-8809-AA53E64B4391Q33373277-CFA70382-B3C1-48B5-80C4-D50464DDF88CQ33398403-7ABA6CE6-86A1-41F7-B7C4-B45A89C01C0CQ33407719-600B6783-B05C-4408-AC5D-49E976369914Q33418525-51987145-0CBF-4CEE-A3FF-BD0EB4FA711CQ33425472-EC52EDF0-62F4-4E27-9E9D-4EAC56A995C9Q33582787-A1DC2D00-75DB-43C6-B5CF-63F5D91E6613Q33628394-0F49A5AD-5A97-4AA4-B721-62AEF99C8708Q33639642-15B8895C-1637-4984-89BB-0F31E42F1518Q33654457-1E990FD4-8B44-4A30-807D-A56DB1D356CCQ33658701-580FEF76-77A8-4FFE-987E-AB755A1F61A1Q33705645-F0818B1B-66E0-4E4C-BC32-5499C7AE6E8FQ33799276-F7EA14A2-E0A3-4DC4-8E82-E3D62A5CC697Q33813860-AC959319-D64B-426F-AE9D-BE07849D5000
P2860
Side effects of therapy of hepatitis C and their management.
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Side effects of therapy of hepatitis C and their management.
@ast
Side effects of therapy of hepatitis C and their management.
@en
Side effects of therapy of hepatitis C and their management.
@nl
type
label
Side effects of therapy of hepatitis C and their management.
@ast
Side effects of therapy of hepatitis C and their management.
@en
Side effects of therapy of hepatitis C and their management.
@nl
prefLabel
Side effects of therapy of hepatitis C and their management.
@ast
Side effects of therapy of hepatitis C and their management.
@en
Side effects of therapy of hepatitis C and their management.
@nl
P2860
P356
P1433
P1476
Side effects of therapy of hepatitis C and their management.
@en
P2093
Michael W Fried
P2860
P304
P356
10.1053/JHEP.2002.36810
P407
P433
P577
2002-11-01T00:00:00Z